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It is well recognized that the immune system and metabolism are highly integrated. In this 
context, multilevel interactions between metabolic system and T lymphocyte signaling and 
fate exist. This review will discuss different potential cell metabolism pathways involved 
in shaping T lymphocyte function and differentiation. We will also provide a general 
framework for understanding how tumor microenvironmental metabolism, associated 
with hypoxic stress, interferes with T-cell priming and expansion. How T-cell metabolism 
drives T-cell-mediated immunity and how the manipulation of metabolic programing for 
therapeutic purposes will be also discussed.
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iNTRODUCTiON
Accumulating evidence indicate that the resolution of antigenic aggression (i.e., cancer and viral 
infection) requires the coordinated response of various heterogeneous immune cell types to a range 
of physiological and pathological signals to regulate their proliferation, migration, differentiation, 
and effector functions (1). One of the mechanisms by which immune cells integrate these signals is 
through the modulation of their metabolic activity (2). The diverse functions of the immune system 
require several bioenergetic processes. The metabolic pathways of oxidative metabolism fuels effector 
functions of immune cells (3, 4). In this regard, effector T cells have been reported to metabolically 
reprogram and upregulate glucose, amino acid, and iron uptake to support the synthesis of the new 
macromolecules necessary for T-cell clonal expansion and effector function (5, 6). While metabolite 
fluctuation caused by host immune cells is at present an active area of study, the pathways involved 
Abbreviations: AAMacs, activated macrophages; ATM, adipose tissue-associated macrophages; ATP, adenosine triphosphate; 
BAT, brown adipose tissue; CTLA-4, cytotoxic T lymphocyte antigen-4; HIF, hypoxia-inducible factor; IFN-γ; interferon-γ; 
ILC2s, Group 2 innate lymphoid cells; iNKT, invariant natural killer T; IR, insulin resistance; mTOR: mammalian target of 
rapamycin; OXPHOS, oxidative phosphorylation; PD-1, programed death-1; PD-L1, programed death ligand-1; TCR, T-cell 
receptor; TGF-β, transforming growth factor beta; TME, tumor microenvironment; WAT, white adipose tissue.
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in T-cell activation and differentiation, in class switching effector 
T cells into memory T cells and how metabolism regulates 
immune function and plasticity remains unclear and very chal-
lenging. It is well established that low oxygen (O2) availability is 
a hallmark of most solid tumors in which infiltrating leukocytes 
experience severe hypoxia once away from nurturing blood ves-
sels (7, 8). Therefore, it is not surprising that pathways of hypoxic 
stress response, largely governed by hypoxia-inducible factors 
(HIF), are highly relevant to the proper function of immune cells 
(9). There is at present a tremendous increase in studying how 
immune cells function in terms of their intracellular metabolism 
and how these metabolic pathways affect the phenotype and 
activation of immune cells. Nevertheless, although how hypoxia 
regulates T-cell metabolism and survival is relatively known (10), 
very little is known about how hypoxia-associated metabolism 
influences T-cell activation and effector function. Clearly, the 
metabolic activity of T cells in the context of tumor microen-
vironment, its heterogeneity, and complexity is an important 
consideration in immunotherapy, as activated T cells go from 
an Oxygen and nutrient-rich environment in the blood vessels 
to a comparatively Oxygen and nutrient-poor environment of 
hypoxic tumors.
Furthermore, reprograming of immune cell metabolic con-
figuration (11) could be profoundly influenced by the metabolic 
microenvironment (12, 13). Human deregulation of systemic 
metabolism, such as obesity development, is often associated 
with altered immune cell metabolism (14). In obesity, the 
expanded adipose tissue (AT) is accompanied by immune cell 
infiltration (15). In turn, the resulting low-grade inflammation 
status constitutes an important initiator of the microenviron-
ment favorable for tumor development. In fact, AT is recognized 
now as potent endocrine organ by secreting pro-inflammatory 
cytokines [such as tumor necrosis factor-alpha (TNF-α) and 
interleukin-6 (IL-6)] and adipokines (such as leptin) in the 
tumor microenvironment, with great significant impact on both 
tumor and immune cells (16).
Obviously, a deeper understanding of these metabolic-related 
issues and their influence on T-cell function may offer new 
therapeutic options in future to boost the efficacy of treatments 
in particular of cancer disease.
T-CeLL MeTABOLiSM iS A KeY 
DeTeRMiNANT iN T-CeLL FATe, 
DiFFeReNTiATiON, AND FUNCTiON
The pathways that control immune cell function and differen-
tiation are intimately linked to cell metabolism. Like other cells, 
T cells use glucose as their primary fuel source for generation 
of adenosine triphosphate (ATP) and it is necessary for their 
survival, growth, activation, proliferation, and cytokine produc-
tion (17). During quiescent state, resting T cells (naive, memory, 
and anergic T cells) have low metabolic requirements that serve 
to fuel basal energy generation and replacement biosynthesis. 
Resting T cells, therefore, have a metabolic balance that favors 
energy production over biosynthesis, and appear to oxidize 
glucose-derived pyruvate along with lipids and amino acids via 
the TCA cycle. Unstimulated thymocytes generate approximately 
96% of their ATP via mitochondrial oxidative phosphorylation 
(OXPHOS) (18). Following activation, stimulated T cells must 
rapidly grow, divide, and exert effector function. Once T cells 
divide, they differentiate to different T-cell subsets, each switch-
ing on distinctive metabolic pathways (Figure 1). Proliferating 
cells must increase ATP production and acquire or synthesize raw 
materials, including lipids, proteins, and nucleic acids (19). To 
do so, proliferating T cells actively reprogram their intracellular 
metabolism from catabolic mitochondrial OXPHOS to glycolysis 
and other anabolic pathways. Despite the more rapid turnover 
of ATP via glycolysis when compared to OXPHOS, aerobic 
glycolysis is much less efficient in terms of the amount of ATP 
generated per molecule of glucose consumed. Furthermore, dur-
ing this metabolic reprograming, glycolysis increases along with 
glutamine oxidation (20). Lipid oxidation, however, decreases 
sharply, and lipid synthesis rather than oxidation is favored. 
T-cell activation is thought to drive principally increased glucose 
uptake accompanied by a rapid increase in Glucose transporter-1 
(Glut-1) expression with upregulating aerobic glycolysis, provid-
ing precursors for biomass synthesis (21). However, when rates 
of glucose and glycolysis are low, mitochondrial ATP production 
plays an important role in activated T-cell function (22, 23). If 
inadequate nutrients are prolonged, this may lead to T-cell anergy 
(24, 25) or T-cell death. In addition to glucose metabolism, T cells 
utilize glutaminolysis to meet their increased bioenergetic and 
biosynthetic demands (26). Although the mitochondrial pool of 
acetyl-CoA is mainly derived from the breakdown of glucose, 
glutaminolysis serves to replenish intermediates of the TCA cycle 
that are redirected into biosynthetic reactions, a process known 
as anaplerosis (27, 28). Furthermore, functionally distinct T-cell 
subsets require distinct energetic and biosynthetic pathways 
to support their specific functional needs (22). Recently, it has 
become increasingly apparent that T-cell activation does not lead 
to a uniform metabolic reprograming in all conditions. Regarding 
metabolic differences between activated T-cell subsets, CD4+ T 
cells have greater metabolic flexibility with respect to energy-rich 
substrates than effector CD8+ T cells. Activated CD4+ T cells 
are thought to increase both glycolysis and OXPHOS; however, 
CD8+ T cells increase glycolysis but may not increase OXPHOS. 
Thus, CD8+ T cells are exquisitely sensitive to the availability 
of glucose. A lowering in glucose concentrations prevents 
CD8+ T-cell activation, proliferation, and interferon-γ (IFN-γ) 
production (29).
An effective T-cell activation requires two signals: an antigen-
specific signal induced by the T-cell receptor (TCR) and a 
co-stimulatory signal delivered by the surface receptor CD28. 
Activation of TCR along with CD28 co-stimulation triggers the 
induction of phosphoinositide-3-kinase (PI3K)-dependent acti-
vation of Akt pathway (30). It has been reported that the induction 
of glucose metabolism during T-cell stimulation is dependent on 
the activation of PI3K. In addition, Akt has been shown to control 
changes in glucose transport and metabolism (31). Therefore, it 
is conceivable that Akt is the PI3K-dependent factor control-
ling glucose metabolism downstream of co-stimulatory signals. 
The Akt pathway activation upregulates Glut-1 expression and 
stimulates its localization to the plasma membrane of T cells, 
FiGURe 1 | Role of T-cell metabolism in shaping T-cell differentiation. Upon activation, activated T cells rapidly switch to aerobic glycolysis, increase glucose 
and glutamine uptake and biomolecules synthesis, supporting cell growth and proliferation. Differentiation of activated T cells into different subsets is due to several 
metabolic and signaling pathways. While Th1, Th2, and Thl7 principally rely on aerobic glycolysis, Tregs and memory T cells upregulate fatty acid oxidation 
controlled by AMPK.
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so facilitating increased glucose uptake (21). Furthermore, Akt 
controls the activation state of the mammalian target of rapa-
mycin (mTOR) (32). In turn, mTOR modulates rates of protein 
synthesis that support cell growth and effector functions (33). 
Besides, mTOR has recently been shown to play a crucial role in 
the commitment to distinct differentiation pathways by CD4+ 
and CD8+ T lymphocytes. It orchestrates the induction of anergy, 
the differentiation fate of CD4+ T cells into inflammatory and 
regulatory subsets, the development of CD8+ memory T cells 
and the regulation of T-cell migration patterns (24, 34). In acti-
vated T lymphocytes, the metabolic transition toward increased 
glycolysis is not only associated with mTOR induction but also 
associated with the expression of additional transcription factors, 
including Mycand HIF-1α able to enforce metabolic phenotypes 
in effector T cells appropriate for their function (35, 36). The role 
of hypoxia via HIFs in the regulation of T-cell metabolism and 
differentiation has been poorly studied in different T-cell subsets. 
A few studies have shown that Hypoxia via HIF-1α plays a vital 
role in the differentiation of Th17 and T regulatory cells. Among 
different T-cell subsets, Th17 are highly glycolytic and rely heavily 
on glycolysis. The upregulation of HIF-1α resulted in high levels 
of glycolysis in Th17 cells by increasing the expression of Glut-1 
and PKM (37). HIF-1α was shown to shift from Th2 to Th17 cells 
differentiation by activating transcription of RORγt and directly 
upregulating IL-17 gene (38). Simultaneously, HIF-1α inhibits 
the T regulatory cells differentiation by targeting Foxp3 (39) for 
proteasomal degradation and, hence, shifting from T reg to Th17 
cells (38).
TUMOR MiCROeNviRONMeNT AND iTS 
ROLe iN MODULATiNG iMMUNe CeLL 
MeTABOLiSM
Altered T-Cell Metabolism in Cancer
The ability of T cells to transition from a naïve to effector or to 
a memory phenotype is profoundly determined by metabolism 
and the metabolic program varies to match the T cells subset 
in order to enable cell survival and function. However, tumor 
microenvironment profoundly influences T-cell metabolism, 
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and in consequence the host immune response. Increasing pieces 
of evidence suggest that T cells in the context of established 
progressing cancers exhibit anergic or exhausted state leading to 
T cell-intrinsic dysfunction. This blunt of T-cell function 
induced-tumor escape from immunosurveillance is ascribed to 
changes in the tumor cells themselves and to immunosuppres-
sive factors in the tumor microenvironment. Regarding their 
metabolic state and effector functions, T cells can exert both 
tumor-suppressive and tumor-promoting effects (40–43). Thus, 
manipulating tumor cells and tumor microenvironment may 
provide a therapeutic approach to improve T-cell metabolism and 
to enhance their functions. Currently, how hostile tumor micro-
environment can affect T-cell immune responses by altering the 
resulting cellular metabolism and leading to immunosuppression 
is attracting major attention in particular the ability of tumors 
to subvert normal immune regulation to their advantage. Tumor 
microenvironment in patients with a variety of solid tumors 
has revealed that a major subset of tumors shows evidence of 
increased immunosuppressive cells, such as regulatory T cells 
(Treg), immunosuppressive cytokines derived as from Treg and 
from tumor cells and poorly functional effector T cells expressing 
molecules capable of preventing T-cell activation (44, 45). It is 
important to underline that CD28 family, such as CTL-associated 
antigen-4 (CTLA-4), and programed death-1 (PD-1), is highly 
expressed on exhausted T cells. Engagement of B7 family members 
with CTLA-4 and PD-1 leads to inhibition instead of activation 
of T cells. Expression of these inhibitory receptors may restrain 
T cells from correctly remodeling their metabolism and, hence, 
dampen their function (46). Accumulating data suggest that the 
immunosuppressive metabolic environment could be further 
enhanced by tumor expression of inhibitory ligands for PD-1 and 
CTLA-4 that inhibits the upregulation of glucose and glutamine 
metabolism following TCR engagement and co-stimulation (47). 
Such inhibitory effect leads to T-cell inactivation and escape of 
tumor cells from immune attack (48, 49). Targeting exhausted 
T cells with the aim of enhancing glycolysis may be a way to 
reactivate these cells. Recent preliminary observations indicate 
that checkpoint blockade therapy alters the metabolic balance 
between tumors and their infiltrating T cells (48).
Metabolic Reprograming of Tumor Cell 
and T-Cell Nutrient Deprivation, the 
warburg effect
Cancer cells require increased rates of glucose and glutamine 
consumption allowing them to produce energy (ATP) and the 
nucleotides, amino acids, and lipids required for proliferation. 
This phenomenon of metabolic reprograming, recognized as 
“Warburg effect,” is now considered one of hallmarks of cancer cells 
(50–52). Cancer is also a disease of altered metabolism. Warburg’s 
aerobic glycolysis is not only a feature of cancer cells. The same 
reprograming to aerobic glycolysis is exhibited, for instance, by 
highly proliferating normal cells, such as activated lymphocytes 
(19). Recently, it has been hypothesized that immunosuppres-
sion in the tumor microenvironment is at least in part driven by 
the inability of T cells to acquire the nutrients to support their 
metabolism (53). In this regard, several lines of evidence suggest 
that the altered T-cell function leading to immune escape is due 
in part to the ability of tumors to subvert normal immune regula-
tion to their advantage (54). It is conceivable that the exacerbated 
glycolytic phenotype of tumors may contribute to a strongly 
immunosuppressive microenvironment. In this regard, tumor 
cells with increased consumption of glucose and glutamine may 
cause nutrient deprivation to effector T cells and the subsequent 
acquisition of anergic phenotype, leading to immunosuppres-
sion. It should be noted that oncogenic mutation BRAF V600E 
(55) induces constitutive activation of the MEK–MAPK pathway, 
leading to enhanced tumor cell proliferation, suppression of 
OXPHOS, and a highly glycolytic rate (56, 57). Because glucose 
and glutamine are crucial for T-cell differentiation and function, 
and their depletion impairs T cells cytolytic activity as well as 
interferon-γ (IFN-γ) production (58), it is most likely that the 
highly glycolytic phenotype of BRAF V600E melanoma may be 
associated with an immunosuppressive microenvironment.
effect of Hypoxic Tumor Microenvironment 
on T-Cell Metabolism and Function
Hypoxia-inducible factors are master regulators of tumor and T-cell 
metabolic responses to hypoxia (7). Hypoxia was shown to inhibit 
human T-cell proliferation, cytokine production, and function 
due to increased lactic acid production by tumor cells within the 
tumor microenvironment (59). Hypoxic microenvironment has 
diverse effects on T-cell responses and several oxygen-dependent 
and oxygen-independent stabilizers of HIFs, mostly HIF-1α has 
been identified in T cells (8). TCR-mediated stabilization of HIF-1 
has been reported following antibody-mediated engagement of 
TCR/CD3 via the PI3K/mTOR pathway leading to increased HIF-
1α protein synthesis (60). TCR-activated T cells also increased 
HIF-1α mRNA synthesis by mechanisms involving protein 
kinase C (PKC) and Ca (2+)/calcineurin (61). Independently of 
TCR stimulation, HIF-1α mRNA is augmented in T cells in the 
presence of TGF-β and/or IL-6 by a mechanism involving STAT3 
(38). Hypoxia can interfere with the differentiation and function 
of immune cells by modulating the expression of co-stimulatory 
receptors and the type of cytokines produced by these cells. It 
has been reported that HIF-1 is involved in the upregulation of 
several co-inhibitory and co-stimulatory receptors, such as PD-1, 
CTLA-4, LAG3, CD137, and OX40, on the surface of hypoxic or 
VHL-deficient T lymphocytes (62). Interestingly, the discovery 
that PD-1 and CTLA-4 are direct transcriptional targets of HIF 
can be of utmost importance since they represent key pathways 
of resistance to immunity. Moreover, under hypoxic conditions, 
TCR activation results in an increase in FOXP3 on CD4 T cells in 
a TGF-β-dependent manner, thereby impacting the differentia-
tion toward Tregs (39). The role of HIF-1a has also been identified 
in promoting the recruitment of Treg cells to the tumor micro-
environment via over-expression of cytokines and chemokines, 
such as TGF-β CCL28 by hypoxic tumor cells (63). The effects of 
hypoxic stress on the killing functions of CD8+ T cells have been 
analyzed by several groups. Recently, deletion of Vhl in CD8+ 
T cells, which resulted in constitutive expression of HIF-1 and 
HIF-2, delayed CD8+ T-cell differentiation into effector cells but 
increased their cytotoxic functions and more interestingly several 
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immune checkpoint receptors were increased in both HIF-1- and 
HIF-2-dependent manner (62). Hypoxia has been shown to both 
increase and inhibit T-cell responses. Roman et al. showed that 
hypoxia increased the secretion of cytokines, such as IFN-α by 
CD4 effector cells (64). By contrast, hypoxia decreased IL-2 
from T lymphocytes resulting in an impaired immune response 
(65). Similarly, hypoxia was shown to decrease activated T-cell 
numbers by increased apoptosis (66). On the other hand, hypoxia 
was demonstrated to increase the survival of antigen-specific T 
cells through upregulation of adrenomedullin (67). Further stud-
ies on how hypoxia-mediated glycolysis may regulate especially 
T-cell differentiation and function in a tumoral context are much 
needed. Moreover, we still need to dissect the potential roles of 
both HIF-1α and HIF-2α in the regulation of T-cell metabolism 
and function.
Stromal endothelial Cell Role in Modulating 
immune Cell Metabolism and Function
Endothelial cell metabolic activity has a significant effect on 
immune cells action and recruitment inside the tumor site 
(68). PHD inhibitors as fumarate/succinate produced by tumor 
cells during tricarboxylic acids cycle, is a potent way of HIF-1α 
stabilization (69). Moreover, several metabolites produced influ-
ence macrophages polarization from M1 to M2 phenotype (70). 
Indeed, the increased arginase 1 levels in macrophages depend 
upon the lactate acidification of the tumor microenvironment, 
thus, reducing the efficacy of the immune response (71). Moreover, 
lactate is efficiently pro-inflammatory through IL-17A secretion 
and inhibition of CTLs (72). Inflammation also consumes glu-
cose, influencing Treg cell differentiation in inflammation (71). 
A consequence of the metabolic signals is the expression in the 
tumor microenvironment of immune checkpoint ligands PD-L1 
and PD-L2 (73, 74).
Besides the direct tumor cell expression of PD-1 ligands, 
which is one of the most potent immune checkpoints to counter-
act in order to permit CTL and NK cells activity, the endothelial 
metabolism might rule first their recruitment and participate to 
their inactivation (75). Stromal and immune cells adopt their 
metabolism to optimally exert their distinctive role as support 
cells in particular conditions, in which each of these stromal 
and immune cells must fulfill specialized functions. Overall, 
these findings highlight a potential consideration for future 
immunotherapy.
CeLL MeTABOLiSM iN TUMOR AND 
NON-TUMOR CeLLS
Normal resting cells produce ATP through an energetically 
efficient metabolic program that serves to meet the energetic 
requirements of maintaining homeostasis (76). During prolif-
eration, normal cells activate metabolic pathways to generate 
sufficient energy to support cell replication, and to satisfy the 
anabolic demands of macromolecular biosynthesis of cell repro-
duction (77). The aerobic glycolysis shift of proliferating cells is 
perfectly controlled by signaling and transcriptional circuitry 
that modulates cell growth. Yet, this metabolic boost is primarily 
fueled by glucose and glutamine and correctly maintained by a 
variety of checkpoints (78).
During malignant transformation, cancer cells show atypical 
metabolic characteristics that support inappropriate cell prolif-
eration. Rapidly proliferating cancer cells is marked by increase 
in glucose uptake and consumption (79), which is metabolized 
to lactate under aerobic glycolysis independently of oxygen 
level and mitochondria damage, referred to as “Warburg effect.” 
Glutamine is another nutrient and important source of nitrogen, 
highly consumed by cancer cells. The growth and persistence of 
tumor cells benefit of increased flux of glycolytic and glutamine 
intermediates, supporting macromolecules biosynthetic path-
ways (80). It should be noted that both genetic and non-genetic 
factors can also directly modulate the metabolism of cancer cells, 
although many of the metabolic alterations are largely similar to 
those in normal proliferating cells (81).
Several mutations that activate oncogenes or inactivate 
tumor-suppressors genes impart cancer cells with the ability 
to disrupt multiple metabolic signaling pathways. Mutation of 
PI3K has been usually associated with cancer metabolism (82). 
This alteration activates the PI3K/AKT/mTOR pathway that 
results in stimulating glucose uptake and glycolysis by affecting 
activities of key glycolytic enzymes, such as hexokinase (HK) 
and phosphofructokinase (PFK) (83, 84). Furthermore, mTOR 
indirectly causes stabilization of HIF-1 (85). HIF-1 activates 
PDK, which inactivates the mitochondrial pyruvate dehydro-
genase complex and thereby inhibits the entry of pyruvate into 
the TCA (86). In addition, mutation of c-Myc oncogene also 
has been described to enhance transcriptional activities of key 
enzymes of glycolysis and glutaminolysis in cancer cells (87, 88). 
More importantly, the tumor-suppressor p53 has been reported 
to support OXPHOS via SCO2 and to suppress glycolysis by 
enhancing TIGAR (89).
OBeSiTY, LOw-GRADe iNFLAMMATiON, 
AND CANCeR
immune Response in Obesity
Several lines of evidence revealed that obesity can cause impair-
ment of immune functions and metabolic homeostasis inducing 
chronic inflammation of white adipose tissue (WAT) and the 
resultant increased circulating concentrations of inflammatory 
markers (90). There is accumulating evidence that expanded AT 
results in increased serum levels of cytokines, such as TNF-α and 
IL-6, in obese individuals (90). Subsequently, the elevated pro-
inflammatory mediators induce the activation of IKKβ/NFκB 
and c-Jun NH(2)-terminal kinase (JNK) pathways, which are 
central coordinator of inflammatory responses (91). The inflam-
matory responses associated with obesity may have detrimental 
metabolic consequences (92). Furthermore, the chronic low-
grade inflammation-associated obesity does not occur only in 
WAT but in many organs, including brown adipose tissue (BAT), 
pancreas, liver, brain, muscle, and intestine. However, WAT 
remains the most studied organ in terms of immune–metabolic 
interactions in obesity (93).
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Adipose tissue is described as a heterogeneous tissue, which 
comprises multiple cell types, including a diverse array of 
immune cells. AT-resident immune cells exert a wide range of 
functions, but can roughly be divided into two groups: on the 
one hand, immune cells that drive AT inflammation and insulin 
resistance (IR) and, on the other hand, immune cells that pro-
tect against these pathologies (92, 94). The first group consists 
of pro-inflammatory cells [activated macrophages (AAMacs), 
neutrophils, Th1 CD4 T cells, CD8 T cells, B cells, DCs, and 
mast cells]; these cells produce TNF-α or IFN-γ, or induce the 
polarization of inflammatory M1 macrophages. Thereby, the 
AT-resident inflammatory immune cells drive T helper 1 (Th1) 
cell response. The second group comprises anti-inflammatory 
cells [M2 macrophages, regulatory CD4 T cells (Tregs), Th2 
CD4 T cells, eosinophils, Group 2 innate lymphoid cells (ILC2s), 
invariant natural killer T (iNKT) cells], which produce IL-10, 
IL-4, or IL-13, and drive Th2 response (15, 95). In the steady 
state, crosstalk between adipocytes and immune cells contrib-
utes to the regulation of available balance of energy stores and 
energy expenditure for survival during times of starvation and 
pathogen challenge (96). There is extensive evidence showing 
that both macrophages and T cells are the most abundant leu-
kocytes implicated in AT biology and appear to be at the center 
of obesity-related inflammation via a positive-Feedback Loop 
(97). Macrophages present significant plasticity and recent data 
showed that during obesity, resident adipose tissue-associated 
macrophages (ATAM) display a polarization state switch from 
an alternatively activated state macrophage (M2) to a more 
pro-inflammatory state macrophage (M1) (98). Yet, obesity is 
accompanied by a progressive infiltration into obese AT of acti-
vated (M1) macrophages (99). These M1 macrophages produce 
pro-inflammatory cytokines, such as IL-1b, IL-6, and TNFα, 
creating a pro-inflammatory environment that blocks adipocyte 
insulin action (100). It is likely that this phenotypic switch could 
be the key to propagating inflammation and IR.
Recently, the functional role of adaptive immune cells has been 
characterized in obesity (101). Cytotoxic T cells seem to regulate 
accumulation, differentiation, and activation of macrophages in 
obese AT. Although the exact mechanism is not well understood, 
it is suggested that effector CD8+ T cells recruitment in obese 
AT precede infiltration and accumulation of pro-inflammatory 
macrophages (102). CD8+ T cells produce IFN-γ that further 
promotes the recruitment and activation of M1 macrophages. In 
turn, M1 macrophages enhance antigen presentation to CD4+  
T cells and induce Th1 cell polarization and proliferation (103, 
104). T-bet-dependent CD4+ Th1 cells produce TNF-α and IFN-γ 
to further potentiate IR in WAT (103, 105). How WAT inflamma-
tion is triggered is not completely understood, but it is suggested 
that lipotoxicity (106), endoplasmic reticulum (ER) stress, and 
Toll-like receptor activation (107) are involved. Collectively, 
regarding the dynamic interactions between immune cells and 
adipocytes in obesity, the CD8+ T cell/classically activated 
macrophage pathway in AT appears to be critical for establishing 
the pro-inflammatory status. Therefore, intervening with ATM, 
T cells directly may represent a therapeutic target for improving 
obesity-induced IR.
Obesity-induced inflammation and Cancer
Adipose tissue has been proposed to contribute to the low-grade 
inflammation and to mediate the responses linking obesity to 
cancer. Both adipocytes and infiltrating immune cells coordinate 
to provide tumorigenic and pro-invasive microenvironment 
conducive to metastatic progression (108). Moreover, it has been 
suggested that the inflammatory cells and cytokines found in 
tumors are more likely to contribute to immunosuppression than 
they are to mount an effective host anti-tumor response (109). In 
fact, AT is recognized now as potent endocrine organ by secret-
ing pro-inflammatory cytokines (such as TNF-α and IL-6) and 
adipokines (such as leptin) in the tumor microenvironment (16). 
Adipokines secreted from cancer-associated adipocytes likely 
form a key component of the paracrine signaling in the tumor 
microenvironment, favorable for tumor growth (110–112). 
Additionally, leptin plays critical roles in the regulation of glucose 
homeostasis and has been implied as an effector of obesity-
induced changes in tumor and stroma cells (113). Leptin intra-
cellular signals through its receptor OBRb involve the activation 
of several pathways commonly triggered by many inflammatory 
cytokines [JAK2/STAT; (MAPK)/extracellular regulated kinases 
1 and 2 (ERK1/2) and PI3K/AKT1, and non-canonical signaling 
pathways: PKC, JNK, and p38 MAP kinase] (114). Within cancer 
development, chemotactic factors are produced causing an influx 
of inflammatory cells. Furthermore, these activated cells within 
the tumor secrete pro-inflammatory cytokines, IL-1, IL-6, IFN-γ, 
TNF-α, and IL-17 (115). In turn, stimulated tumor cells by these 
cytokines induce the production of CCLL22, a chemokine that 
then recruits Tregs into the tumor (16, 116). Hence, therapeutic 
modulation of obesity-associated pathways could be an interest-
ing target to improve immune function in cancer.
New MeTABOLiC TARGeTS AND ReCeNT 
APPROACHeS TO MODULATe TUMOR 
MiCROeNviRONMeNT MeTABOLiSM FOR 
THeRAPeUTiC PURPOSeS
Conceiving new therapeutic approaches to target cancer 
metabolism is a real challenge and may prove difficult given that 
cancer cells share similar metabolic requirements than normal 
proliferating cells. Moreover, under metabolic rewiring, cancer 
cells generate thereby an important diversity and heterogeneity 
in the metabolic adaptation. Indeed, such heterogeneity is largely 
potentiated by both genetic and non-genetic factors (81).
Beyond glycolysis, targeting glycolytic enzymes has been 
exploited through therapeutic intervention that might specifi-
cally inhibit key metabolic steps associated with tumor growth, 
proliferation, and invasion. In fact, attenuation of rate-limiting 
steps of glycolysis is an attractive field of investigation for can-
cer metabolism therapy. Currently, several studies have been 
explored small molecules that block glycolysis by inhibition of 
key enzymes (117). In this context, an example of therapeutic 
opportunity is a glucose analog 2-deoxy-d-glucose (2-DG), 
which is a competitive inhibitor of glycolysis (118). Another 
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glycolytic inhibitor is DCA that targets PDK1 and thereby reduce 
lactate production and enhance mitochondrial OXPHOS (119). 
Nonetheless, and given the recognition that metabolic repro-
graming potentiates nucleic acid synthesis to promote tumor 
proliferation, the pentose phosphate pathway (PPP) has been also 
targeted. 6-Aminonicotinamide (6-AN) is a molecule showing an 
inhibitory effect on 6-phosphate dehydrogenase (G6PD), a key 
enzyme of glycolytic shunt into PPP (120, 121). All these drugs 
showed promising results in pre-clinical studies and warrant 
further investigation for clinical trials confirmation.
Another metabolic target that has been explored is mTOR 
pathway, the activation of which is widely described to be involved 
in metabolic reprograming of many human cancers (122–124).
Intensive efforts are underway to directly target inhibition of 
HIF-1 activity for cancer therapy (125). Several directions were 
aimed to test this inhibiting efficacy on HIF-1 transcriptional 
activity and DNA binding, HIF-1 protein translation, and HIF-1 
protein degradation. Accordingly, an increasing number of 
chemical inhibitors have been developed, respectively, to these 
mechanisms of action.
DiSCUSSiON
Accumulating evidence highlights how metabolic adaptations 
of stromal and immune cells determine their differentiation 
and function in health and disease. More importantly metabolic 
changes in these cells may contribute to the pathogenesis of cancer 
and inflammatory diseases. There is growing evidence that extra-
cellular signals are required to upregulate lymphocyte nutrient 
uptake and metabolism to support cell growth, proliferation, and 
cytokine secretion. In this regard, the control of T-cell metabolism 
seems to be important in the effector/memory transition of T cells. 
This opens the possibility that the signaling pathways involved in 
lymphocyte metabolic control may be novel therapeutic targets. 
Despite the significant progress during the last decades in anti-
tumor immunotherapy approaches, there is still a need for more 
innovative approaches integrating the simultaneous activation of 
immune effector cells in the context of metabolic tumor micro-
environment. It is now clear that the behavior of lymphocytes 
and other leukocytes are controlled on many levels by internal 
metabolic properties. The elucidation of how the metabolic phe-
notype of activated T cells is influenced by the microenvironment 
is in this regard very challenging. It is also crucial to understand 
the implication of metabolism in reprograming these cells as well 
as the interplay between their metabolic and cellular signaling 
systems to improve the outcome of cancer immunotherapy. In 
addition, several examples illustrate the therapeutic potential of 
targeting metabolism in stromal and immune cells. Analyzing 
the metabolism of immune cell types is at present a challenging 
issue and may, therefore, have translational consequences. It is 
tempting to speculate that an in-depth study of the signaling 
pathways involved in lymphocyte metabolic control may lead to 
the discovery of several novel immunotherapeutic targets.
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